Sierra-Ascencio Manuel Enrique, Ríos-Vaca Aurelio, Reza-Albarrán Alfredo
Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirdán, México D.F., México.
Gac Med Mex. 2006 Nov-Dec;142(6):483-91.
Exenatide is the first synthetic agonist of the GLP-1 (glucagon-like peptide 1) receptor approved for clinical use in patients with type 2 diabetes. The multiplicity of its effects over glucose metabolism, appetite, body weight and its potential capacity to preserve the ?cell mass, makes it an attractive therapeutic alternative. This article attempts to review the current literature on pharmacokinetics, pharmacodynamics, efficacy, and safety of exenatide in humans, derived from the early phase I and II studies, and from the clinical controlled trials that led to its approval for clinical use as a combination therapy with sulphonylureas and metformin.
艾塞那肽是首个被批准用于2型糖尿病患者临床治疗的胰高血糖素样肽-1（GLP-1）受体合成激动剂。它在葡萄糖代谢、食欲、体重方面具有多种作用，并且具有保护β细胞量的潜在能力，这使其成为一种有吸引力的治疗选择。本文旨在综述有关艾塞那肽在人体中的药代动力学、药效学、疗效和安全性的现有文献，这些文献来源于早期的I期和II期研究，以及使其获批与磺脲类药物和二甲双胍联合用于临床治疗的临床对照试验。
